Andrea Bertotti
Overview
Explore the profile of Andrea Bertotti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
6340
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Perron U, Grassi E, Chatzipli A, Viviani M, Karakoc E, Trastulla L, et al.
Nat Commun
. 2024 Nov;
15(1):9139.
PMID: 39528460
Patient-derived xenografts (PDXs) are tumour fragments engrafted into mice for preclinical studies. PDXs offer clear advantages over simpler in vitro cancer models - such as cancer cell lines (CCLs) and...
2.
Pessei V, Macagno M, Mariella E, Congiusta N, Battaglieri V, Battuello P, et al.
Genome Med
. 2024 Oct;
16(1):118.
PMID: 39385243
Background: Liquid biopsy based on cell-free DNA (cfDNA) analysis holds significant promise as a minimally invasive approach for the diagnosis, genotyping, and monitoring of solid malignancies. Human tumors release cfDNA...
3.
Leto S, Grassi E, Avolio M, Vurchio V, Cottino F, Ferri M, et al.
Nat Commun
. 2024 Aug;
15(1):7495.
PMID: 39209908
The breadth and depth at which cancer models are interrogated contribute to the successful clinical translation of drug discovery efforts. In colorectal cancer (CRC), model availability is limited by a...
4.
Cortese M, Torchiaro E, DAndrea A, Petti C, Invrea F, Franco L, et al.
Mol Ther
. 2024 Jun;
32(8):2741-2761.
PMID: 38894542
HER2 amplification occurs in approximately 5% of colorectal cancer (CRC) cases and is associated only partially with clinical response to combined human epidermal growth factor receptor 2 (HER2)/epidermal growth factor...
5.
Malla S, Byrne R, Lafarge M, Corry S, Fisher N, Tsantoulis P, et al.
Nat Genet
. 2024 Jun;
56(6):1321.
PMID: 38831011
No abstract available.
6.
Malla S, Byrne R, Lafarge M, Corry S, Fisher N, Tsantoulis P, et al.
Nat Genet
. 2024 Feb;
56(3):458-472.
PMID: 38351382
Molecular stratification using gene-level transcriptional data has identified subtypes with distinctive genotypic and phenotypic traits, as exemplified by the consensus molecular subtypes (CMS) in colorectal cancer (CRC). Here, rather than...
7.
Singh H, Sahgal P, Kapner K, Corsello S, Gupta H, Gujrathi R, et al.
Clin Cancer Res
. 2024 Feb;
30(8):1669-1684.
PMID: 38345769
Purpose: ERBB2-amplified colorectal cancer is a distinct molecular subtype with expanding treatments. Implications of concurrent oncogenic RAS/RAF alterations are not known. Experimental Design: Dana-Farber and Foundation Medicine Inc. Colorectal cancer...
8.
Beekhof R, Bertotti A, Bottger F, Vurchio V, Cottino F, Zanella E, et al.
Sci Transl Med
. 2023 Aug;
15(709):eabm3687.
PMID: 37585503
Epidermal growth factor receptor (EGFR) is a well-exploited therapeutic target in metastatic colorectal cancer (mCRC). Unfortunately, not all patients benefit from current EGFR inhibitors. Mass spectrometry-based proteomics and phosphoproteomics were...
9.
Cascianelli S, Barbera C, Ulla A, Grassi E, Lupo B, Pasini D, et al.
Genome Med
. 2023 May;
15(1):37.
PMID: 37189167
Background: Transcriptional classification has been used to stratify colorectal cancer (CRC) into molecular subtypes with distinct biological and clinical features. However, it is not clear whether such subtypes represent discrete,...
10.
Pernice S, Sirovich R, Grassi E, Viviani M, Ferri M, Sassi F, et al.
Bioinformatics
. 2023 Apr;
39(5).
PMID: 37079732
Motivation: The transition from evaluating a single time point to examining the entire dynamic evolution of a system is possible only in the presence of the proper framework. The strong...